Signifor™ (pasireotide injection) is indicated for the treatment of Cushing’s disease. Pasireotide exerts therapeutic effects by binding to somatostatin receptors resulting in ACTH inhibition and decreased cortisol secretion. Adverse effects include diarrhea, nausea, hyperglycemia, cholelithiasis, headache, abdominal pain, fatigue, and diabetes mellitus.

**Recommended authorization criteria**

Pasireotide is prescribed by, or in consultation, with an endocrinologist.

**FDA-approved indications**

1. **Cushing’s disease.** Approve for 3 months of initial therapy if the patient meets the following criteria (i, ii, and iii):
   i. Patient is ≥ 18 years of age AND
   ii. The patient is not a candidate for surgery, or surgery has not been curative AND
   iii. Failure of at least one prior agent used in the treatment of Cushing’s disease (ketoconazole, mitotane, or metyrapone) or contraindication to all agents

Continued approvals will require documentation of clinical benefit of the medication.

**Exclusions (Limitations)**

1. Acromegaly
2. Neuroendocrine tumors
3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.
References